Proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) in the Hospital medicines list


31 March 2017 - PHARMAC is seeking feedback on a proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) through a provisional agreement with Specialised Therapeutics Limited.

5-aminolevulinic acid hydrochloride (Gliolan) is used for visualisation of malignant tissue during neurosurgery.

Details of the proposal are set out below, in summary, if progressed, it would result in aminolevulinic acid hydrochloride being funded by DHB hospitals, subject to restrictions, for the adjuvant treatment of patients with newly diagnosed, untreated, glioblastoma multiforme undergoing fluorescence-guided resection.

Read PHARMAC Consultation

Michael Wonder

Posted by:

Michael Wonder